Skip to main content

Table 2 Assessment schedule

From: SAFE (Sarpogrelate Anplone in Femoro-popliteal artery intervention Efficacy) study: study protocol for a randomized controlled trial

Visit date

Visit 1

Visit 2

Visit 3

Visit 4

0 day

14 days

3 months

6 months

Demographic data

   

Medical/surgical history

   

Concomitant diseases

 

Concomitant medication/treatment

 

Physical examination (vital signs)

Laboratory results (CBC, LFT, PT INR)

ABI

CTA or angiography

  

Adverse events

 

  1. CBC complete blood cell count, LFT liver function test, PT prothrombin time International Normalized Ratio, ABI ankle–brachial index, CTA computed tomography angiography